The IFIT1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population from the human NCI-H1975 lung adenocarcinoma epithelial cell line, designed to disrupt the IFIT1 gene. This heterogeneous pool enables functional studies of IFIT1 in a non-small cell lung cancer background. The polyclonal format suits experiments where clonal variability is not a concern and a rapid, cost-effective model is needed. Cells are provided as a ready-to-use population for immediate expansion and assays.
The host NCI-H1975 line models human lung adenocarcinoma with EGFR L858R/T790M and TP53 mutations. Derived from a non-smoking patient, it is relevant for studying EGFR-mutant non-small cell lung cancer and acquired resistance to EGFR TKIs. The EGFR double mutant provides sensitivity to first-generation inhibitors but resistance to later ones, while TP53 mutation models genomic instability.
IFIT1 (Interferon-Induced Protein with Tetratricopeptide Repeats 1) is a critical effector of type I interferon antiviral responses. It is transcriptionally induced by IFN??, IFN??, and IFN?? via the JAK-STAT pathway, downstream of STAT1, STAT2, and IRF9 binding to ISRE elements. IFIT1 recognizes and sequesters viral 5′-pppRNA, inhibiting viral mRNA translation through interactions with eIF3. It complexes with IFIT2 and IFIT3, and its activity is integrated within the RIG-I/MDA5 pathway. Upstream regulators include IRF3, IRF7, and NF-??B. Downstream, IFIT1 suppresses viral replication and may modulate actin dynamics and apoptosis.
In the context of EGFR-mutant NCI-H1975 cells, knockout of IFIT1 provides a unique platform to dissect the intersection of oncogenic signaling and innate immunity. The loss of IFIT1 disrupts the cell??s ability to mount an interferon-driven antiviral state, allowing researchers to study how EGFR-driven proliferation and survival signals interact with innate immune pathways. Given emerging evidence that interferon responses can influence tumor cell fitness, this knockout model may reveal tumor-suppressive or tumor-promoting roles of IFIT1. Furthermore, the TP53-mutant background may cooperate with IFIT1 loss to alter cell cycle regulation and apoptosis, offering insights into synthetic lethal relationships and potential vulnerabilities in lung adenocarcinoma.
Typical applications include investigating innate immune evasion mechanisms, evaluating interferon signaling dynamics in lung cancer, and conducting functional analyses of viral restriction factors. The model is suitable for drug resistance studies, particularly exploring how loss of interferon-responsive genes affects sensitivity to targeted therapies. Researchers may employ assays such as Western blotting, RT-qPCR, interferon-stimulated antiviral plaque assays, RNA-seq, flow cytometry for apoptosis/cell cycle, migration/invasion assays, co-immunoprecipitation with eIF3, and luciferase reporter assays to dissect IFIT1 functions. For additional details, please contact Ascent Research.
